^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Sulanda (surufatinib)

    i
    Other names: HMPL-012, HMPL012, HMPL 012
    Company:
    Hutchmed
    Drug class:
    VEGFR inhibitor, VEGFR-2 inhibitor, CSF-1R inhibitor, FGFR1 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor
    Related drugs:
    3d
    Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (ChiCTR2500114518)
    P4, N=350, Not yet recruiting, Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University
    New P4 trial
    |
    Sulanda (surufatinib)
    3d
    Phase Ⅱ Clinical Study of Surufatinib Combined with Temozolomide as First-line Therapy for Pulmonary Neuroendocrine Tumors (ChiCTR2600116780)
    P2, N=27, Not yet recruiting, The Second Affiliated hospital of Fujian Medical University; The Second Affiliated hospital of Fujian Medical University
    New P2 trial
    |
    temozolomide • Sulanda (surufatinib)
    3d
    Surufatinib for advanced or metastatic chemotherapy-refractory thymic malignancies: a single-arm, single-center, phase II study (ChiCTR2600116776)
    P2, N=20, Completed, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    Sulanda (surufatinib)
    3d
    Surufatinib combined with toripalimab, albumin - bound paclitaxel and radiotherapy for first - line treatment of advanced esophageal cancer:A single - arm, open - label, phase II clinical study (ChiCTR2600116673)
    P2, N=30, Completed, Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital; The First Medical Center, Chinese
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Sulanda (surufatinib)
    12d
    Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=96, Recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    carboplatin • temozolomide • capecitabine • Sulanda (surufatinib)
    18d
    Systemic Therapy for Advanced Pheochromocytoma and Paraganglioma: Real-World Evidence from a Single Center Cohort. (PubMed, Endocr Relat Cancer)
    In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.
    Journal • HEOR • Real-world evidence
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    temozolomide • Sulanda (surufatinib)
    1m
    2023-012-00CH1: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=502, Recruiting, Hutchmed | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> May 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    ZSPAC-17: Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (clinicaltrials.gov)
    P4, N=350, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Sulanda (surufatinib)
    2ms
    Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • Sulanda (surufatinib)
    2ms
    Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Sulanda (surufatinib)
    2ms
    ZSPAC-17: Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (clinicaltrials.gov)
    P4, N=350, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • Real-world evidence
    |
    Sulanda (surufatinib)
    2ms
    Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med)
    Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • Sulanda (surufatinib)